A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine
Latest Information Update: 28 May 2025
At a glance
- Drugs Respiratory syncytial virus vaccine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
Most Recent Events
- 02 May 2025 Planned End Date changed from 10 Mar 2028 to 24 Feb 2028.
- 02 May 2025 Planned primary completion date changed from 10 Mar 2028 to 24 Feb 2028.
- 02 May 2025 Status changed from not yet recruiting to recruiting.